NICE reviewed various technologies and recommended DERM as the only AI tool suitable for NHS use. It is the first dermatology ...

Lecanemab, currently licensed as a biweekly 10 mg/kg IV infusion, is developed by Eisai and Biogen to address the unmet needs of AD patients. AD, a chronic, progressive disease and the UK’s leading ...